Detalles de la búsqueda
1.
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
BMC Cancer
; 24(1): 541, 2024 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38684948
2.
Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe.
Future Oncol
; 19(31): 2103-2121, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37706245
3.
Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models.
Eur J Haematol
; 93 Suppl 75: 9-18, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24966141
4.
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Oncol Ther
; 11(2): 263-275, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37014590
5.
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Oncol Ther
; 11(3): 313-326, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37270762
6.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 39(1): 81-89, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271807
7.
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Clin Lymphoma Myeloma Leuk
; 23(1): 68-77, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36357295
8.
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
Cancer Rep (Hoboken)
; 5(11): e1603, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35168299
9.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clin Drug Investig
; 42(1): 29-41, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34822128
10.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): 690-701, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764490
11.
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.
EJHaem
; 3(1): 97-108, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846215
12.
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(5): 326-335, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34840088
13.
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 38(10): 1759-1767, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815818
14.
Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
Clin Drug Investig
; 41(3): 201-210, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33598857
15.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 37(10): 1779-1788, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34256668
16.
Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.
Med Care
; 48(11): 947-54, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20856141
17.
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
J Med Econ
; 22(8): 777-787, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982378
18.
Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.
J Child Adolesc Psychopharmacol
; 17(2): 195-203, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17489714
19.
Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
BMC Health Serv Res
; 7: 122, 2007 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-17663768
20.
The burden of non-radiographic axial spondyloarthritis.
Semin Arthritis Rheum
; 44(5): 556-562, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25532945